Advertisement

Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling

  • Florian SchererEmail author
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 215)

Abstract

Most malignancies are characterized by remarkable molecular heterogeneity. The understanding of genetic and epigenetic processes underlying tumor heterogeneity has become increasingly important for the clinical management of cancer patients. This includes the identification of patients who likely benefit from conventional or targeted therapies, classification of patients into risk groups based on their mutational landscape, and the detection of molecular mechanisms that drive treatment resistance and cancer progression. Detection of tumor heterogeneity by tumor tissue genotyping is hampered by the fact that tissue sampling is often insufficient for comprehensive genetic assessment and is associated with a higher risk of surgical complications. Detection and profiling of circulating tumor DNA (ctDNA) have emerged as a promising alternative to direct tumor genotyping. It potentially enables noninvasive and quantitative characterization of the full genetic landscape and identification of clonal evolution during treatment and towards disease progression in cancer patients. In the present chapter, we explore the role of noninvasive genotyping and ctDNA profiling for accurate and robust characterization of various types of tumor heterogeneity and its relevance for management of patients with hematologic and solid cancers.

Keywords

Tumor heterogeneity Clonal evolution Circulating tumor DNA High-throughput sequencing Therapy-resistant subclones Noninvasive relapse detection 

Notes

Acknowledgements

The author would like to thank J. Kress for assistance with the graphical design.

References

  1. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R et al (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545(7655):446–451. PubMed PMID: 28445469. Epub 2017/04/27Google Scholar
  2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503–511. PubMed PMID: 10676951. Epub 2000/02/17PubMedCrossRefPubMedCentralGoogle Scholar
  3. Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C et al (2015) Toward understanding and exploiting tumor heterogeneity. Nat Med 21(8):846–853. PubMed PMID: 26248267. Pubmed Central PMCID: 4785013. Epub 2015/08/08PubMedPubMedCentralCrossRefGoogle Scholar
  4. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6(224):224ra24. PubMed PMID: 24553385. Pubmed Central PMCID: 4017867. Epub 2014/02/21Google Scholar
  5. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ et al (2016a) Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815. PubMed PMID: 27283993. Pubmed Central PMCID: 4906406. Epub 2016/06/11Google Scholar
  6. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ et al (2016b) Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:13513. PubMed PMID: 27841271. Pubmed Central PMCID: 5114547. Epub 2016/11/15Google Scholar
  7. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J et al (2013) Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 59(1):211–224. PubMed PMID: 23065472. Epub 2012/10/16PubMedCrossRefPubMedCentralGoogle Scholar
  8. Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gensheimer MF, West RB, Shrager JB, Neal JW, Wakelee HA, Loo BW, Alizadeh AA, Diehn M (2017) Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery 7(12):1394–1403PubMedPubMedCentralCrossRefGoogle Scholar
  9. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Molin MD, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Vogelstein JT, Browne JD, Schoen RE, Brand RE, Tie J, Gibbs P, Wong HL, Mansfield AS, Jen J, Hanash SM, Falconi M, Allen PJ, Zhou S, Bettegowda C, Diaz LA, Tomasetti C, Kinzler KW, Vogelstein B, Lennon AM, Papadopoulos N (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359(6378):926–930PubMedPubMedCentralCrossRefGoogle Scholar
  10. Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SO, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, Rooijen KL, Ørntoft MW, Madsen AH, Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE (2019) Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570(7761):385–389PubMedCrossRefPubMedCentralGoogle Scholar
  11. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF et al (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. New Engl J Med 368(13):1199–1209. PubMed PMID: 23484797. Epub 2013/03/15PubMedCrossRefPubMedCentralGoogle Scholar
  12. De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P et al (2014) Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol Off J Eur Soc Med Oncol 25(9):1729–1735. PubMed PMID: 25009010. Epub 2014/07/11Google Scholar
  13. De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martinez-Ricarte F, Torrejon D et al (2015) Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6:8839. PubMed PMID: 26554728. Pubmed Central PMCID: 5426516. Epub 2015/11/12Google Scholar
  14. Devonshire AS, Whale AS, Gutteridge A, Jones G, Cowen S, Foy CA et al (2014) Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 406(26):6499–6512. PubMed PMID: 24853859. Pubmed Central PMCID: 4182654. Epub 2014/05/24PubMedPubMedCentralCrossRefGoogle Scholar
  15. Diaz LA, Jr., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486(7404):537–540. PubMed PMID: 22722843. Pubmed Central PMCID: 3436069. Epub 2012/06/23CrossRefGoogle Scholar
  16. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D (2006) BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nature Methods 3(7):551–559. PubMed PMID: 16791214. Epub 2006/06/23PubMedCrossRefPubMedCentralGoogle Scholar
  17. Do K, O’Sullivan Coyne G, Chen AP (2015) An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Chin Clin Oncol 4(3):31. PubMed PMID: 26408298. Epub 2015/09/27Google Scholar
  18. Ferreira MP, Ferreira NP, Pereira Filho Ade A, Pereira Filho Gde A, Franciscatto AC (2006) Stereotactic computed tomography-guided brain biopsy: diagnostic yield based on a series of 170 patients. Surg Neurol 65(Suppl 1):S1:27–1:32. PubMed PMID: 16427444. Epub 2006/01/24CrossRefGoogle Scholar
  19. Fontanilles M, Marguet F, Bohers E, Viailly PJ, Dubois S, Bertrand P et al (2017) Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget. PubMed PMID: 28636991. Epub 2017/06/22Google Scholar
  20. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F et al (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4(136):136ra68. PubMed PMID: 22649089. Epub 2012/06/01CrossRefGoogle Scholar
  21. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl J Med 366(10):883–892. PubMed PMID: 22397650. Epub 2012/03/09Google Scholar
  22. Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S et al (2017) Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov 7(9):1006–1017. PubMed PMID: 28450425. Epub 2017/04/30PubMedPubMedCentralCrossRefGoogle Scholar
  23. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282. PubMed PMID: 14504078. Epub 2003/09/25PubMedPubMedCentralCrossRefGoogle Scholar
  24. Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol Off J Am Soc Clin Oncol 32(5):415–423. PubMed PMID: 24297946. Epub 2013/12/04PubMedCrossRefPubMedCentralGoogle Scholar
  25. Hiley C, de Bruin EC, McGranahan N, Swanton C (2014) Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol 15(8):453. PubMed PMID: 25222836. Pubmed Central PMCID: 4281956. Epub 2014/09/16Google Scholar
  26. Horak P, Klink B, Heining C, Groschel S, Hutter B, Frohlich M et al (2017) Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer 141(5):877–886. PubMed PMID: 28597939. Epub 2017/06/10PubMedCrossRefPubMedCentralGoogle Scholar
  27. Jain N, Keating MJ (2016) Richter transformation of CLL. Exp Rev Hematol 9(8):793–801. PubMed PMID: 27351634. Epub 2016/06/29PubMedCrossRefPubMedCentralGoogle Scholar
  28. Jain D, Sharma MC, Sarkar C, Deb P, Gupta D, Mahapatra AK (2006) Correlation of diagnostic yield of stereotactic brain biopsy with number of biopsy bits and site of the lesion. Brain Tumor Pathol 23(2):71–75. PubMed PMID: 18095122. Epub 2007/12/21PubMedCrossRefPubMedCentralGoogle Scholar
  29. Jamal-Hanjani M, Wilson GA, Horswell S, Mitter R, Sakarya O, Constantin T et al (2016) Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol 27(5):862–867. PubMed PMID: 26823523. Epub 2016/01/30PubMedCrossRefPubMedCentralGoogle Scholar
  30. Jamroziak K, Tadmor T, Robak T, Polliack A (2015) Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. Leuk Lymphoma 56(7):1949–1958. PubMed PMID: 25356923. Epub 2014/10/31CrossRefGoogle Scholar
  31. Kennedy SR, Schmitt MW, Fox EJ, Kohrn BF, Salk JJ, Ahn EH et al (2014) Detecting ultralow-frequency mutations by Duplex sequencing. Nat Protoc 9(11):2586–2606. PubMed PMID: 25299156. Pubmed Central PMCID: 4271547. Epub 2014/10/10PubMedPubMedCentralCrossRefGoogle Scholar
  32. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B (2011) Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 108(23):9530–9535. PubMed PMID: 21586637. Pubmed Central PMCID: 3111315. Epub 2011/05/19CrossRefGoogle Scholar
  33. Kridel R, Sehn LH, Gascoyne RD (2017) Can histologic transformation of follicular lymphoma be predicted and prevented? Blood 130(3):258–266. PubMed PMID: 28408460. Epub 2017/04/15PubMedCrossRefPubMedCentralGoogle Scholar
  34. Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA et al (2015) Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125(24):3679–3687. PubMed PMID: 25887775. Pubmed Central PMCID: 4463733. Epub 2015/04/19PubMedPubMedCentralCrossRefGoogle Scholar
  35. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA (2018) Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol 36(28):2845–2853PubMedPubMedCentralCrossRefGoogle Scholar
  36. Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA (2019) Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell 178(3):699–713.e19PubMedCrossRefPubMedCentralGoogle Scholar
  37. Kwapisz D (2017) The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med 5(3):46. PubMed PMID: 28251125. Pubmed Central PMCID: 5326656. Epub 2017/03/03PubMedPubMedCentralCrossRefGoogle Scholar
  38. Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A et al (2016) Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci U S A 113(13):E1826–E1834. PubMed PMID: 26976580. Pubmed Central PMCID: 4822610. Epub 2016/03/16CrossRefGoogle Scholar
  39. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM (2008) Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 14(5):579–584. PubMed PMID: 18408729. Epub 2008/04/15PubMedCrossRefPubMedCentralGoogle Scholar
  40. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R (1993) p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82(8):2289–2295. PubMed PMID: 8400281. Epub 1993/10/15Google Scholar
  41. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl J Med 362(25):2380–2388. PubMed PMID: 20573926. Epub 2010/06/25PubMedCrossRefPubMedCentralGoogle Scholar
  42. Maier J, Lange T, Kerle I, Specht K, Bruegel M, Wickenhauser C et al (2013) Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA. Clin Cancer Res Off J Am Assoc Cancer Res 19(17):4854–4867. PubMed PMID: 23833305. Epub 2013/07/09PubMedCrossRefPubMedCentralGoogle Scholar
  43. Malone H, Yang J, Hershman DL, Wright JD, Bruce JN, Neugut AI (2015) Complications following stereotactic needle biopsy of intracranial tumors. World Neurosurg 84(4):1084–1089. PubMed PMID: 26008141. Epub 2015/05/27PubMedCrossRefPubMedCentralGoogle Scholar
  44. Manoj N, Arivazhagan A, Bhat DI, Arvinda HR, Mahadevan A, Santosh V et al (2014) Stereotactic biopsy of brainstem lesions: techniques, efficacy, safety, and disease variation between adults and children: a single institutional series and review. J Neurosci Rural Pract 5(1):32–39. PubMed PMID: 24741247. Pubmed Central PMCID: 3985354. Epub 2014/04/18PubMedPubMedCentralCrossRefGoogle Scholar
  45. Medina Diaz I, Nocon A, Mehnert DH, Fredebohm J, Diehl F, Holtrup F (2016) Performance of Streck cfDNA blood collection tubes for liquid biopsy testing. PLoS ONE 11(11):e0166354. PubMed PMID: 27832189. Pubmed Central PMCID: 5104415 study. FD is an inventor on patents related to the BEAMing technology (patents US8715934 B2, “Single-molecule PCR on microparticles in water-in-oil emulsions”; US9360526 B2, “Methods for BEAMing”; and US9360526 B2, “Improved methods for BEAMing”). The Safe-SeqS technology is in development at Sysmex Inostics. OncoBEAM is a product of Sysmex Inostics and is based on the BEAMing technology. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. Epub 2016/11/11Google Scholar
  46. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D et al (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404):532–536. PubMed PMID: 22722830. Pubmed Central PMCID: 3927413. Epub 2012/06/23PubMedPubMedCentralCrossRefGoogle Scholar
  47. Molina TJ, Canioni D, Copie-Bergman C, Recher C, Briere J, Haioun C et al (2014) Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d’Etudes des Lymphomes de l’Adulte/lymphoma study association phase III trial LNH 03–2B. J Clin Oncol Off J Am Soc Clin Oncol 32(35):3996–4003. PubMed PMID: 25385729. Epub 2014/11/12PubMedCrossRefPubMedCentralGoogle Scholar
  48. Montoto S, Fitzgibbon J (2011) Transformation of indolent B-cell lymphomas. J Clin Oncol Off J Am Soc Clin Oncol 29(14):1827–1834. PubMed PMID: 21483014. Epub 2011/04/13PubMedCrossRefPubMedCentralGoogle Scholar
  49. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497(7447):108–112. PubMed PMID: 23563269. Epub 2013/04/09Google Scholar
  50. Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J et al (2015) Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun 6:8760. PubMed PMID: 26530965. Pubmed Central PMCID: 4659935. Epub 2015/11/05Google Scholar
  51. Narayan A, Carriero NJ, Gettinger SN, Kluytenaar J, Kozak KR, Yock TI et al (2012) Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res 72(14):3492–3498. PubMed PMID: 22581825. Pubmed Central PMCID: 3426449. Epub 2012/05/15PubMedPubMedCentralCrossRefGoogle Scholar
  52. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA et al (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20(5):548–554. PubMed PMID: 24705333. Pubmed Central PMCID: 4016134. Epub 2014/04/08PubMedPubMedCentralCrossRefGoogle Scholar
  53. Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F et al (2016) Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 34(5):547–555. PubMed PMID: 27018799. Pubmed Central PMCID: 4907374. Epub 2016/03/29PubMedPubMedCentralCrossRefGoogle Scholar
  54. Norton SE, Lechner JM, Williams T, Fernando MR (2013) A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem 46(15):1561–1565. PubMed PMID: 23769817. Epub 2013/06/19PubMedCrossRefPubMedCentralGoogle Scholar
  55. Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD et al (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol Off J Am Soc Clin Oncol 33(3):251–257. PubMed PMID: 25135992. Epub 2014/08/20PubMedCrossRefPubMedCentralGoogle Scholar
  56. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M et al (2016) Association between plasma genotyping and outcomes of treatment with Osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 34(28):3375–3382. PubMed PMID: 27354477. Pubmed Central PMCID: 5035123. Epub 2016/06/30PubMedPubMedCentralCrossRefGoogle Scholar
  57. Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H et al (2016) Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med 13(12):e1002198. PubMed PMID: 27997533. Pubmed Central PMCID: 5172526 following competing interests: DG, NR and JDB are co-founders, shareholders and officers/consultants of Inivata Ltd, a cancer genomics company that commercialises ctDNA analysis. Epub 2016/12/21PubMedPubMedCentralCrossRefGoogle Scholar
  58. Perdigones N, Murtaza M (2017) Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis. Pharmacol Ther 174:22–26. PubMed PMID: 28167216. Epub 2017/02/09CrossRefGoogle Scholar
  59. Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J et al (2017) Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med 9(403). PubMed PMID: 28814544. Epub 2017/08/18PubMedPubMedCentralGoogle Scholar
  60. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P et al (2017) Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov 7(9):999–1005. PubMed PMID: 28450426. Pubmed Central PMCID: 5581695. Epub 2017/04/30PubMedPubMedCentralCrossRefGoogle Scholar
  61. Reuter JA, Spacek DV, Snyder MP (2015) High-throughput sequencing technologies. Mol Cell 58(4):586–597. PubMed PMID: 26000844. Pubmed Central PMCID: 4494749. Epub 2015/05/23PubMedPubMedCentralCrossRefGoogle Scholar
  62. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. New Engl J Med 372(1):30–39. PubMed PMID: 25399551. Epub 2014/11/18PubMedCrossRefPubMedCentralGoogle Scholar
  63. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161(5):1215–1228. PubMed PMID: 26000489. Pubmed Central PMCID: 4484602. Epub 2015/05/23Google Scholar
  64. Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K et al (2015) Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 16(5):541–549. PubMed PMID: 25842160. Pubmed Central PMCID: 4460610. Epub 2015/04/07PubMedPubMedCentralCrossRefGoogle Scholar
  65. Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K et al (2011) The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 117(12):3391–3401. PubMed PMID: 21266718. Epub 2011/01/27PubMedCrossRefPubMedCentralGoogle Scholar
  66. Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S et al (2017) Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. PubMed PMID: 28096087. Epub 2017/01/18Google Scholar
  67. Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS et al (2016a) Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 8(364):364ra155. PubMed PMID: 27831904. Epub 2016/11/11PubMedPubMedCentralCrossRefGoogle Scholar
  68. Scherer F, Kurtz DM, Newman AM, Esfahani MS, Craig A, Stehr H et al (2016b) Development and validation of biopsy-free genotyping for molecular subtyping of diffuse large B-cell lymphoma. Blood 128:1089Google Scholar
  69. Scherer F, Kurtz DM, Diehn M, Alizadeh AA (2017) High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood 130(4):440–452. PubMed PMID: 28600337. Epub 2017/06/11PubMedPubMedCentralCrossRefGoogle Scholar
  70. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA (2012) Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A 109(36):14508–14513. PubMed PMID: 22853953. Pubmed Central PMCID: 3437896. Epub 2012/08/03CrossRefGoogle Scholar
  71. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y et al (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403):395–399. PubMed PMID: 22495314. Pubmed Central PMCID: 3863681. Epub 2012/04/13Google Scholar
  72. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G et al (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21(7):827. PubMed PMID: 26151329. Epub 2015/07/08Google Scholar
  73. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J (2016) Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 164(1–2):57–68. PubMed PMID: 26771485. Pubmed Central PMCID: 4715266. Epub 2016/01/16PubMedPubMedCentralCrossRefGoogle Scholar
  74. Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH et al (2015) Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A 112(40):E5503–12. PubMed PMID: 26392541. Pubmed Central PMCID: 4603482. Epub 2015/09/24CrossRefGoogle Scholar
  75. Sun K, Jiang P, Cheng SH, Cheng THT, Wong J, Wong VWS, Ng SSM, Ma BBY, Leung TY, Chan SL, Mok TSK, Lai PBS, Chan HLY, Sun H, Chan KCA, Chiu RWK, Lo YMD (2019) Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. Genome Res 29(3):418–427PubMedPubMedCentralCrossRefGoogle Scholar
  76. Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X et al (2013) Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 59(12):1722–1731. PubMed PMID: 23938455. Epub 2013/08/14PubMedCrossRefPubMedCentralGoogle Scholar
  77. Tannock IF, Hickman JA (2016) Limits to personalized cancer medicine. New Engl J Med 375(13):1289–1294. PubMed PMID: 27682039. Epub 2016/09/30PubMedCrossRefPubMedCentralGoogle Scholar
  78. Thompson JD, Shibahara G, Rajan S, Pel J, Marziali A (2012) Winnowing DNA for rare sequences: highly specific sequence and methylation based enrichment. PLoS ONE 7(2):e31597. PubMed PMID: 22355378. Pubmed Central PMCID: 3280224. Epub 2012/02/23PubMedPubMedCentralCrossRefGoogle Scholar
  79. Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H et al (2015a) EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90(3):509–515. PubMed PMID: 26494259. Epub 2015/10/24PubMedCrossRefPubMedCentralGoogle Scholar
  80. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B et al (2015b) Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21(6):560–562. PubMed PMID: 25939061. Pubmed Central PMCID: 4771182. Epub 2015/05/06PubMedPubMedCentralCrossRefGoogle Scholar
  81. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127–1134. PubMed PMID: 15451219. Epub 2004/09/29CrossRefGoogle Scholar
  82. Vogelstein B, Kinzler KW (1999) Digital PCR. Proc Natl Acad Sci U S A 96(16):9236–9241. PubMed PMID: 10430926. Pubmed Central PMCID: 17763. Epub 1999/08/04CrossRefGoogle Scholar
  83. von Bubnoff N (2017) Liquid biopsy: approaches to dynamic genotyping in cancer. Oncol Res Treat 40(7–8):409–416. PubMed PMID: 28693026. Epub 2017/07/12PubMedCrossRefPubMedCentralGoogle Scholar
  84. Wan JC, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C et al (2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17(4):223–238. PubMed PMID: 28233803. Epub 2017/02/25PubMedCrossRefPubMedCentralGoogle Scholar
  85. Waterhouse M, Follo M, Pfeifer D, von Bubnoff N, Duyster J, Bertz H et al (2016) Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR. Ann Hematol 95(5):739–744. PubMed PMID: 26931113. Epub 2016/03/05PubMedCrossRefPubMedCentralGoogle Scholar
  86. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922–926. PubMed PMID: 26193343. Epub 2015/07/21PubMedCrossRefPubMedCentralGoogle Scholar
  87. Yano T, Jaffe ES, Longo DL, Raffeld M (1992) MYC rearrangements in histologically progressed follicular lymphomas. Blood 80(3):758–767. PubMed PMID: 1638027. Epub 1992/08/01Google Scholar
  88. Yeh P, Dickinson M, Ftouni S, Hunter T, Sinha D, Wong SQ et al (2017a) Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. Blood 129(12):1685–1690. PubMed PMID: 28126926. Epub 2017/01/28PubMedCrossRefPubMedCentralGoogle Scholar
  89. Yeh P, Hunter T, Sinha D, Ftouni S, Wallach E, Jiang D et al (2017b) Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. Nat Commun 8:14756. PubMed PMID: 28303898. Pubmed Central PMCID: 5357854. Epub 2017/03/18Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Hematology, Oncology, and Stem Cell Transplantation, University Medical Center FreiburgAlbert-Ludwigs-UniversityFreiburgGermany

Personalised recommendations